InsidersTradesSigma
EQL Pharma AB Stock: price and management transactions · Finland · FIN-FSA
Follow the EQL Pharma AB share price and the full management transaction log of the company, a listed equity based in Finland. Shares are listed on FI FI, under the oversight of FIN-FSA. Operating in the Health Care sector, EQL Pharma AB has published 3 insider filings. Market capitalisation: €772.2m. The latest transaction was reported on 30 December 2025 (Purchase). Among the most active insiders: Martin Kristofferson. Every trade is free.
3
Insider Decl.
0
Thresholds
€238,161
3 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate EQL Pharma AB Strong Buy (bullish), based on 1 analysts. Average price target: SEK 50.00.
20Σ signal
Fundamental score
Ranked 21,449 of 26,179 companies
29.3
score / 100
Value27
Quality32
FCF yld-5.2%
Earn yld1.7%
EV/EBITDA25.2x
ROE-1.1%
Gross mgn38%
Net mgn2.9%
Debt/EBITDA10.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 30 December 2025
Declarations3 total
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
1,000 shares@ €5.3350.0007% mcap100.0% of flowAktieFI:A003V099-1
Ideal exit: 26 Sept 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
19,225 shares@ €4.81060.012% mcap39.7% of flowAktieFI:A003V027-1
Ideal exit: 19 Sept 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
23,300 shares@ €6.02330.018% mcap60.3% of flowAktieFI:A003S639-1
Ideal exit: 22 Jun 2026 (T+270)
3 of 3 declarations